{"id":336,"date":"2025-03-27T06:17:00","date_gmt":"2025-03-27T05:17:00","guid":{"rendered":"https:\/\/www.neuromuscularbcn.org\/?page_id=336"},"modified":"2025-04-29T10:55:28","modified_gmt":"2025-04-29T08:55:28","slug":"miastenia-gravis","status":"publish","type":"page","link":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/","title":{"rendered":"Miast\u00e8nia Gravis"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1422.72px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column cnt_PagGen_Content_col\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\" data-scroll-devices=\"small-visibility,medium-visibility,large-visibility\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-tabs fusion-tabs-1 classic nav-is-justified cnt_pestanas horizontal-tabs icon-position-left mobile-mode-carousel mobile-sticky-tabs\" style=\"--awb-title-border-radius-top-left:0px;--awb-title-border-radius-top-right:0px;--awb-title-border-radius-bottom-right:0px;--awb-title-border-radius-bottom-left:0px;--awb-alignment:start;--awb-inactive-color:#ffffff;--awb-background-color:var(--awb-color1);--awb-border-color:#ffffff;--awb-active-border-color:var(--awb-color5);\"><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\" role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-793a55cff9d6f159a60\" aria-selected=\"true\" id=\"fusion-tab-informaci\u00f3general\" href=\"#tab-793a55cff9d6f159a60\"><h4 class=\"fusion-tab-heading\">Informaci\u00f3 General<\/h4><\/a><\/li><li role=\"presentation\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-78d3bcdca2504cf1645\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-publicacions\" href=\"#tab-78d3bcdca2504cf1645\"><h4 class=\"fusion-tab-heading\">Publicacions<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-informaci\u00f3general\" id=\"tab-793a55cff9d6f159a60\">\n<h6>Informaci\u00f3 General<\/h6>\n<p><img decoding=\"async\" class=\"alignnone wp-image-2706\" src=\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg\" alt=\"\" width=\"941\" height=\"193\" srcset=\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1-200x41.jpg 200w, https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1-300x62.jpg 300w, https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1-400x82.jpg 400w, https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1-600x123.jpg 600w, https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1-768x158.jpg 768w, https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1-800x164.jpg 800w, https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg 1024w\" sizes=\"(max-width: 941px) 100vw, 941px\" \/><\/p>\n<p>La Miast\u00e8nia Gravis (MG) \u00e9s una malaltia neurol\u00f2gica greu. \u00c9s una malaltia autoimmune mediada per anticossos enfront de diferents ant\u00edgens de la uni\u00f3 neuromuscular. Majorit\u00e0riament els anticossos s\u00f3n contra\u00a0 Receptor Acetilcolina (RAch) i en menor grau \u00a0contra kinasa m\u00fascul espec\u00edfica, MuKS o altres prote\u00efnes com LRP4 o Cortactin.<\/p>\n<p>La investigaci\u00f3 que el nostre grup realitza en el camp de la Miast\u00e8nia \u00e9s traslacional, i molt dirigida a millorar el diagn\u00f2stic i el tractament dels pacients a trav\u00e9s del coneixement dels mecanismes immunol\u00f2gics que condueixen a la malaltia.<\/p>\n<p><strong>Recerca en Diagn\u00f2stic de MG<\/strong>: De fet, la investigaci\u00f3 en el camp del diagn\u00f2stic de la MG va ser la pionera en el nostre grup ja que en col\u00b7laboraci\u00f3 amb el Dr. Juarez del Servei d\u2019Immunologia, vam posar en marxa a Espanya la determinaci\u00f3 dels anticossos antireceptors d\u2019acetilcolina (Ac. Rach). El desenvolupament de la t\u00e8cnica i la correlaci\u00f3 dels anticossos amb els subgrups de pacients amb MG va ser el tema de la tesi doctoral de la Dra. Illa, defensada a la UAB el 1986. Posteriorment, el 2004, vam posar a punt la t\u00e8cnica de detecci\u00f3 dels anticossos antiMusK, per al diagn\u00f2stic d\u2019un subgrup concret de MG. Vam ser i som pioners a Espanya en la determinaci\u00f3 de tots dos anticossos, aix\u00ed com m\u00e9s recentment d\u2019anticossos anti-cortactin i LRP4, per al diagn\u00f2stic de MG, rebent mostres procedents de diversos centres d\u2019Espanya.<\/p>\n<p>En aquest moment participem en un estudi internacional per validar una escala de valoraci\u00f3 de l\u2019estat cl\u00ednic dels pacients per tal que sigui \u00fatil per al seguiment dels pacients i quantifiqui el d\u00e8ficit de manera que els canvis terap\u00e8utics siguin m\u00e9s f\u00e0cilment objectivables. En l\u2019estudi, amb lideratge al Canad\u00e0, participen pa\u00efsos que s\u2019expressen en diferents idiomes i s\u2019anomena \u201cCross cultural validation of the Myasthenia Gravis impairment index\u201d, \u201cMGII- espanyol\u201d.<\/p>\n<p><strong>Pel que fa a la investigaci\u00f3 terap\u00e8utica<\/strong>,<\/p>\n<p>el gener del 2012 vam publicar en Neurology la revista de m\u00e9s prestigi en Neurologia Cl\u00ednica la \u00a0nostra experi\u00e8ncia en el tractament de pacients amb MG, resistent a altres ter\u00e0pies, amb Rituximab. \u201cLong-lasting treatment effect of rituximab in Musk myasthenia\u201d. Neurology. 2012 Jan 17; 78 (3): 189-93. Els resultats, han merescut que l\u2019article s\u2019assenyal\u00e9s com d\u2019alta qualitat docent, amb un podcast en Neurology. Aquest article s\u2019ha convertit en referent d\u2019algoritmes de tractament de la Miast\u00e8nia resistent a altres tractaments immunosupressors, motiu pel qual ens van convidar a publicar la nostra experi\u00e8ncia \u201cMyasthenia gravis and the neuromuscular junction\u201d. Curr Opin Neurol. 2013 octubre; 26 (5): 459-65, a presentar els resultats en reunions internacionals com a ponents i a participar en les guies Internacionals publicades recentment a Neurology \u201cInternational consensus guidance for management of myasthenia gravis: Executive summary.\u201d Neurology. 2016 juliol 26; 87 (4): 419-25. doi: 10.1212 \/ WNL.0000000000002790.<\/p>\n<p>A m\u00e9s hem participat en el dif\u00edcil projecte de demostrar si la timectomia era efica\u00e7 en el tractament de la MG que ha estat publicat a la revista m\u00e8dica m\u00e9s prestigiosa, New Engl J Med. Sent part del MGTX Study Group. \u201cRandomized Trial of Thymectomy in Myasthenia Gravis\u201d. N Engl J Med. 2016 Aug 11; 375 (6): 511-22. doi: 10.1056 \/ NEJMoa1602489.<\/p>\n<p>Els nostres objectius investigadors en el camp del tractament s\u00f3n sempre molt actius, participant actualment en 3 assaigs cl\u00ednics amb f\u00e0rmacs innovadors, en la classificaci\u00f3 i tractament dels timomas, i en l\u2019outcome de la timectomia per toracospia.<\/p>\n<p>Pel que fa als<strong>\u00a0mecanismes immunopatol\u00f2gics que condueixen a la malaltia,<\/strong>\u00a0els nostres objectius en els pr\u00f2xims tres anys es centren en :<\/p>\n<ol>\n<li>trobar nous ant\u00edgens en aquells casos de MG (al voltant del 15%) en els quals els pacients s\u00f3n seronegatius per als autoant\u00edgens coneguts , utilitzant per a aix\u00f2 una metodologia molt especialitzada i desenvolupada amb \u00e8xit en el nostre anterior FIS 13\/0937<\/li>\n<li>Determinar si l\u2019estudi de l\u2019activitat funcional dels autoanticossos (antiRAch i \/ o antiMuSK), aix\u00ed com la glicosilaci\u00f3 dels autoanticossos o la pres\u00e8ncia de polimorfismes en la prote\u00efna Decay-Accelarating Factor seran millors biomarcadors que els t\u00edtols d\u2019anticossos per al seguiment cl\u00ednic i la selecci\u00f3 de tractaments.<\/li>\n<li>caracteritzar els mecanismes cel\u00b7lulars i moleculars implicats en la immunopatog\u00e8nia de la resposta mediada per IgG4 a la MG-MuSK i en la seva resposta excel\u00b7lent i mantinguda amb el tractament amb el f\u00e0rmac biol\u00f2gic antiCD20 + Rituximab. Per a aix\u00f2 es realitzar\u00e0:\n<ol>\n<li>An\u00e0lisi seriat de les subclasses d\u2019IgG<\/li>\n<li>Estudi observacional transversal de la nostra s\u00e8rie de pacients i la de l\u2019Univ. de Yale, amb major nombre de recidives<\/li>\n<li>En col\u00b7laboraci\u00f3 amb l\u2019Univ. de Zuric realitzarem un estudi de citometria de masses CyTOF de mostres de pacients pre i post tractament amb Rituximab. Basant-nos en els resultats experimentals i utilitzant les nostres bases de dades s\u2019establiran correlacions cl\u00ednica per a un millor diagn\u00f2stic, seguiment i per a la selecci\u00f3 de tractaments immunol\u00f2gics espec\u00edfics dels pacients amb MG. Per a la realitzaci\u00f3 d\u2019aquests estudis comptem amb el finan\u00e7ament del Fons d\u2019Investigaci\u00f3 Sanit\u00e0ria PI16 \/ 01440 \u201cEstudis moleculars i cel\u00b7lulars en Miast\u00e8nia Gravis: Correlacions cl\u00edniques i terap\u00e8utiques\u201d<\/li>\n<\/ol>\n<\/li>\n<\/ol>\n<p><a href=\"https:\/\/www.neuromuscularbcn.org\/staff\/isabel-illa-sendra\/\"><em><strong>PI. Isabel Illa<\/strong><\/em><\/a><\/p>\n<\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-publicacions\" id=\"tab-78d3bcdca2504cf1645\">\n<h6 id=\"tit_anclaje1\" class=\"anclaje_btn_cab\">Publicacions<\/h6>\n<div class=\"cnt_publicaciones\"><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2023<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36697230\">Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis.<\/a><\/div><div class=\"cnt_autores\">\u00c1lvarez-Velasco R, Dols-Icardo O, El Bounasri S, L\u00f3pez-Vilar\u00f3 L, Trujillo JC, Reyes-Leiva D, Su\u00e1rez-Calvet X, Cort\u00e9s-Vicente E, Illa I, Gallardo E<\/div><div class=\"cnt_rev\">Neurol Neuroimmunol Neuroinflamm<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2022<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36240543\">Enrichment of serum IgG4 in MuSK myasthenia gravis patients.<\/a><\/div><div class=\"cnt_autores\">Vergoossen DLE, Ruiter AM, Keene KR, Niks EH, Tannemaat MR, Strijbos E, Lipka AF, van der Zijde ECJ, van Tol MJD, Bakker JA, Wevers BA, Westerberg E, Borges LS, Tong OC, Richman DP, Illa I, Punga AR, Evoli A, van der Maarel SM, Verschuuren JJ, Huijbers MG<\/div><div class=\"cnt_rev\">J Neuroimmunol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35811274\">Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia.<\/a><\/div><div class=\"cnt_autores\">Caballero-\u00c1vila M, \u00c1lvarez-Velasco R, Moga E, Rojas-Garcia R, Turon-Sans J, Querol L, Oliv\u00e9 M, Reyes-Leiva D, Illa I, Gallardo E, Cort\u00e9s-Vicente E<\/div><div class=\"cnt_rev\">Neuromuscul Disord<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35728947\">Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.<\/a><\/div><div class=\"cnt_autores\">Reyes-Leiva D, L\u00f3pez-Contreras J, Moga E, Pla-Junc\u00e0 F, Lynton-Pons E, Rojas-Garcia R, Turon-Sans J, Querol L, Olive M, \u00c1lvarez-Velasco R, Caballero-\u00c1vila M, Carbayo \u00c1, Vesperinas-Castro A, Domingo P, Illa I, Gallardo E, Cort\u00e9s-Vicente E<\/div><div class=\"cnt_rev\">Neurol Neuroimmunol Neuroinflamm<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35080153\">Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.<\/a><\/div><div class=\"cnt_autores\">Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T, Casasnovas C, G\u00f3mez-Caravaca MT, Pardo J, Ramos-Fransi A, Pelayo-Negro AL, Guti\u00e9rrez-Guti\u00e9rrez G, Turon-Sans J, L\u00f3pez de Munain A, Guerrero-Sola A, Jeric\u00f3 I, Mart\u00edn MA, Mendoza MD, Mor\u00eds G, V\u00e9lez-G\u00f3mez B, Garcia-Sobrino T, Pascual-Go\u00f1i E, Reyes-Leiva D, Illa I, Gallardo E<\/div><div class=\"cnt_rev\">Ann Clin Transl Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2021<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34590717\">Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.<\/a><\/div><div class=\"cnt_autores\">Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F, REGAIN Study Group<\/div><div class=\"cnt_rev\">Muscle Nerve<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34273889\">Comment to \"Autoantibodies to cortactin and agrin in sera of patients with myasthenia gravis\".<\/a><\/div><div class=\"cnt_autores\">Cort\u00e9s-Vicente E, Alv\u00e1rez-Velasco R, Illa I, Gallardo E<\/div><div class=\"cnt_rev\">J Neuroimmunol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33721382\">Clinical characteristics and outcomes of thymoma-associated myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">\u00c1lvarez-Velasco R, Guti\u00e9rrez-Guti\u00e9rrez G, Trujillo JC, Mart\u00ednez E, Segovia S, Arribas-Velasco M, Fern\u00e1ndez G, Paradas C, V\u00e9lez-G\u00f3mez B, Casasnovas C, Nedkova V, Guerrero-Sola A, Ramos-Fransi A, Mart\u00ednez-Pi\u00f1eiro A, Pardo J, Sevilla T, G\u00f3mez-Caravaca MT, L\u00f3pez de Munain A, Jeric\u00f3 I, Pelayo-Negro AL, Mart\u00edn MA, Morgado Y, Mendoza MD, P\u00e9rez-P\u00e9rez H, Rojas-Garc\u00eda R, Turon-Sans J, Querol L, Gallardo E, Illa I, Cort\u00e9s-Vicente E<\/div><div class=\"cnt_rev\">Eur J Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33229455\">Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.<\/a><\/div><div class=\"cnt_autores\">Mantegazza R, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O'Brien FL, Booth HDE, Howard JF Jr, REGAIN Study Group<\/div><div class=\"cnt_rev\">Neurology<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33144515\">International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.<\/a><\/div><div class=\"cnt_autores\">Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J<\/div><div class=\"cnt_rev\">Neurology<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2020<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33212055\">COVID-19-associated risks and effects in myasthenia gravis (CARE-MG).<\/a><\/div><div class=\"cnt_autores\">Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, Tavee JO, Kaminski H, Howard JF Jr, Cutter G, Wiendl H, Maas MB, Illa I, Mantegazza R, Murai H, Utsugisawa K, Nowak RJ, CARE-MG Study Group<\/div><div class=\"cnt_rev\">Lancet Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32700461\">Consistent improvement with eculizumab across muscle groups in myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr, REGAIN study group<\/div><div class=\"cnt_rev\">Ann Clin Transl Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32189108\">'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.<\/a><\/div><div class=\"cnt_autores\">Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF, REGAIN study group<\/div><div class=\"cnt_rev\">J Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32247193\">Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.<\/a><\/div><div class=\"cnt_autores\">International MG\/COVID-19 Working Group, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF Jr, Illa I, Mantegazza R, Murai H, Utsugisawa K, Vissing J, Wiendl H, Nowak RJ<\/div><div class=\"cnt_rev\">J Neurol Sci<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32071167\">Clinical and therapeutic features of myasthenia gravis in adults based on age at onset.<\/a><\/div><div class=\"cnt_autores\">Cort\u00e9s-Vicente E, \u00c1lvarez-Velasco R, Segovia S, Paradas C, Casasnovas C, Guerrero-Sola A, Pardo J, Ramos-Fransi A, Sevilla T, L\u00f3pez de Munain A, G\u00f3mez MT, Jeric\u00f3 I, Guti\u00e9rrez-Guti\u00e9rrez G, Pelayo-Negro AL, Mart\u00edn MA, Mendoza MD, Mor\u00eds G, Rojas-Garcia R, D\u00edaz-Manera J, Querol L, Gallardo E, V\u00e9lez B, Albert\u00ed MA, Gal\u00e1n L, Garc\u00eda-Sobrino T, Mart\u00ednez-Pi\u00f1eiro A, Lozano-Veintimilla A, Fern\u00e1ndez-Torr\u00f3n R, Cano-Abascal \u00c1, Illa I<\/div><div class=\"cnt_rev\">Neurology<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2019<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31698177\">Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.<\/a><\/div><div class=\"cnt_autores\">Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K, REGAIN Study Group<\/div><div class=\"cnt_rev\">J Neurol Sci<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31115842\">Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr, REGAIN Study Group<\/div><div class=\"cnt_rev\">Qual Life Res<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30905021\">Eculizumab improves fatigue in refractory generalized myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr, REGAIN Study Group<\/div><div class=\"cnt_rev\">Qual Life Res<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30767274\">Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr, Regain Study Group<\/div><div class=\"cnt_rev\">Muscle Nerve<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30692052\">Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.<\/a><\/div><div class=\"cnt_autores\">Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Str\u00f6bel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR, MGTX Study Group<\/div><div class=\"cnt_rev\">Lancet Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2018<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29928654\">The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">Cort\u00e9s-Vicente E, Rojas-Garcia R, D\u00edaz-Manera J, Querol L, Casasnovas C, Guerrero-Sola A, Mu\u00f1oz-Blanco JL, B\u00e1rcena-Llona JE, M\u00e1rquez-Infante C, Pardo J, Mart\u00ednez-Fern\u00e1ndez EM, Us\u00f3n M, Oliva-Nacarino P, Sevilla T, Illa I<\/div><div class=\"cnt_rev\">Ann Clin Transl Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29068555\">Diagnostic utility of cortactin antibodies in myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">Illa I, Cort\u00e9s-Vicente E, Mart\u00ednez M\u00c1, Gallardo E<\/div><div class=\"cnt_rev\">Ann N Y Acad Sci<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2017<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29066163\">Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.<\/a><\/div><div class=\"cnt_autores\">Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R, REGAIN Study Group<\/div><div class=\"cnt_rev\">Lancet Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25449965\">Prevalence of myasthenia gravis in the Catalan county of Osona.<\/a><\/div><div class=\"cnt_autores\">Aragon\u00e8s JM, Altimiras J, Roura P, Alonso F, Bufill E, Munmany A, Alfonso S, Illa I<\/div><div class=\"cnt_rev\">Neurologia<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2016<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27379450\">Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin.<\/a><\/div><div class=\"cnt_autores\">Cort\u00e9s-Vicente E, Gallardo E, Mart\u00ednez M\u00c1, D\u00edaz-Manera J, Querol L, Rojas-Garc\u00eda R, Illa I<\/div><div class=\"cnt_rev\">JAMA Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27509100\">Randomized Trial of Thymectomy in Myasthenia Gravis.<\/a><\/div><div class=\"cnt_autores\">Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Str\u00f6bel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR, MGTX Study Group<\/div><div class=\"cnt_rev\">N Engl J Med<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27358333\">International consensus guidance for management of myasthenia gravis: Executive summary.<\/a><\/div><div class=\"cnt_autores\">Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P<\/div><div class=\"cnt_rev\">Neurology<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26857500\">Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.<\/a><\/div><div class=\"cnt_autores\">Huijbers MG, Vink AF, Niks EH, Westhuis RH, van Zwet EW, de Meel RH, Rojas-Garc\u00eda R, D\u00edaz-Manera J, Kuks JB, Klooster R, Straasheijm K, Evoli A, Illa I, van der Maarel SM, Verschuuren JJ<\/div><div class=\"cnt_rev\">J Neuroimmunol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2015<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26032110\">The expanding field of IgG4-mediated neurological autoimmune disorders.<\/a><\/div><div class=\"cnt_autores\">Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, Dalmau J, Illa I, Verschuuren JJ<\/div><div class=\"cnt_rev\">Eur J Neurol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25847221\">Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry.<\/a><\/div><div class=\"cnt_autores\">Ramos-Fransi A, Rojas-Garc\u00eda R, Segovia S, M\u00e1rquez-Infante C, Pardo J, Coll-Cant\u00ed J, Jeric\u00f3 I, Illa I, Myasthenia NMD-ES Study Group<\/div><div class=\"cnt_rev\">Eur J Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2014<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25193850\">Cortactin autoantibodies in myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">Gallardo E, Mart\u00ednez-Hern\u00e1ndez E, Titulaer MJ, Huijbers MG, Mart\u00ednez MA, Ramos A, Querol L, D\u00edaz-Manera J, Rojas-Garc\u00eda R, Hayworth CR, Verschuuren JJ, Balice-Gordon R, Dalmau J, Illa I<\/div><div class=\"cnt_rev\">Autoimmun Rev<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24637658\">Analysis of serum miRNA profiles of myasthenia gravis patients.<\/a><\/div><div class=\"cnt_autores\">Nogales-Gadea G, Ramos-Fransi A, Su\u00e1rez-Calvet X, Navas M, Rojas-Garc\u00eda R, Mosquera JL, D\u00edaz-Manera J, Querol L, Gallardo E, Illa I<\/div><div class=\"cnt_rev\">PLoS One<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25180387\">Myasthenia gravis: a disease of the very old.<\/a><\/div><div class=\"cnt_autores\">Aragon\u00e8s JM, Roura-Poch P, Hern\u00e1ndez-Ocampo EM, Alonso F, Pont-Lluelles M, Xandri I, Bol\u00edbar I, Illa I<\/div><div class=\"cnt_rev\">J Am Geriatr Soc<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2013<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23945282\">Myasthenia gravis and the neuromuscular junction.<\/a><\/div><div class=\"cnt_autores\">Querol L, Illa I<\/div><div class=\"cnt_rev\">Curr Opin Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2012<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22775575\">Treatment strategies for myasthenia gravis: an update.<\/a><\/div><div class=\"cnt_autores\">D\u00edaz-Manera J, Rojas Garc\u00eda R, Illa I<\/div><div class=\"cnt_rev\">Expert Opin Pharmacother<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22218276\">Long-lasting treatment effect of rituximab in MuSK myasthenia.<\/a><\/div><div class=\"cnt_autores\">D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L, Klooster R, Rojas-Garc\u00eda R, Su\u00e1rez-Calvet X, Mu\u00f1oz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Ju\u00e1rez C, Verschuuren JJ, Illa I<\/div><div class=\"cnt_rev\">Neurology<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2011<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21387375\">Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia.<\/a><\/div><div class=\"cnt_autores\">Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, Wilson C, Jacobs D, Lai M, Walker RW, Graus F, Bataller L, Illa I, Markx S, Strauss KA, Peles E, Scherer SS, Dalmau J<\/div><div class=\"cnt_rev\">Ann Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2010<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20402760\">Guidelines for treatment of autoimmune neuromuscular transmission disorders.<\/a><\/div><div class=\"cnt_autores\">Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, Hilton-Jones D, Melms A, Verschuuren J, Horge HW, European Federation of Neurological Societies<\/div><div class=\"cnt_rev\">Eur J Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2009<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19445561\">Treatment strategies for myasthenia gravis.<\/a><\/div><div class=\"cnt_autores\">D\u00edaz-Manera J, Rojas-Garc\u00eda R, Illa I<\/div><div class=\"cnt_rev\">Expert Opin Pharmacother<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2008<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18653247\">Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.<\/a><\/div><div class=\"cnt_autores\">Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E<\/div><div class=\"cnt_rev\">J Neuroimmunol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2007<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17611489\">Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.<\/a><\/div><div class=\"cnt_autores\">D\u00edaz-Manera J, Rojas-Garc\u00eda R, Gallardo E, Ju\u00e1rez C, Mart\u00ednez-Dome\u00f1o A, Mart\u00ednez-Ram\u00edrez S, Dalmau J, Blesa R, Illa I<\/div><div class=\"cnt_rev\">Nat Clin Pract Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2005<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15989843\">[\"Seronegative\" myasthenia gravis and antiMuSK positive antibodies: description of Spanish series].<\/a><\/div><div class=\"cnt_autores\">Illa I, D\u00edaz-Manera JA, Ju\u00e1rez C, Rojas-Garc\u00eda R, Molina-Porcel L, Aleu A, Pradas J, Gallardo E<\/div><div class=\"cnt_rev\">Med Clin (Barc)<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15959667\">IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.<\/a><\/div><div class=\"cnt_autores\">Illa I<\/div><div class=\"cnt_rev\">J Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">2003<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12654975\">Myasthenia gravis: a higher than expected incidence in the elderly.<\/a><\/div><div class=\"cnt_autores\">Aragon\u00e8s JM, Bol\u00edbar I, Bonfill X, Bufill E, Mummany A, Alonso F, Illa I<\/div><div class=\"cnt_rev\">Neurology<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12531976\">Anti-titin antibodies are not associated with a specific thymoma histology.<\/a><\/div><div class=\"cnt_autores\">Voltz R, Albrich W, Hohlfeld R, Nagel D, Wick M, Kirchner T, Sommer N, Illa I, Kaminski H, Schumm F<\/div><div class=\"cnt_rev\">J Neurol Neurosurg Psychiatry<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">1999<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10482280\">Acute bulbar weakness: thyrotoxicosis or myasthenia gravis?<\/a><\/div><div class=\"cnt_autores\">Lle\u00f3 A, Sanahuja J, Serrano C, Rojas R, Illa I<\/div><div class=\"cnt_rev\">Ann Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">1996<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8982124\">Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barr\u00e9 syndrome, myasthenia gravis and dermatomyositis.<\/a><\/div><div class=\"cnt_autores\">Basta M, Illa I, Dalakas MC<\/div><div class=\"cnt_rev\">J Neuroimmunol<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8768678\">[Intravenous immunoglobulins in the treatment of neurologic diseases].<\/a><\/div><div class=\"cnt_autores\">Illa I, Serrano C<\/div><div class=\"cnt_rev\">Neurologia<\/div><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8755214\">[Erythroblastopenia during recurrence of a thymoma associated with myasthenia gravis. Apropos of a new case].<\/a><\/div><div class=\"cnt_autores\">Montserrat I, Sard\u00e0 P, L\u00f3pez R, Illa I, Bordes R, Ayats R<\/div><div class=\"cnt_rev\">Sangre (Barc)<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">1995<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7595682\">Myasthenia gravis coincident with papillary thyroid carcinoma: absent expression of the alpha-subunit of the acetylcholine receptor in the tumour.<\/a><\/div><div class=\"cnt_autores\">Illa I, Vila N, Gallardo E, Graus F<\/div><div class=\"cnt_rev\">J Neurol<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">1990<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2361025\">[Predictive factors of the response to treatment of myasthenia gravis with prednisone].<\/a><\/div><div class=\"cnt_autores\">Pradas J, Illa I<\/div><div class=\"cnt_rev\">Neurologia<\/div><\/div><\/div><\/div><div class=\"cnt_year\"><div class=\"cnt_articulo cnt_articulo_year\"><div class=\"cnt_year_pub\">1986<\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_year_pub\"><\/div><\/div><div class=\"cnt_txt\"><\/div><\/div> <div class=\"cnt_articulo\"><div class=\"cnt_year_pub\"><\/div><div class=\"cnt_sep\"><div class=\"circ_sep sep_arti_pub\"><\/div><\/div><div class=\"cnt_txt\"><div class=\"cnt_title\"><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3736183\">[Eaton-Lambert syndrome. Long-term treatment with corticoids].<\/a><\/div><div class=\"cnt_autores\">Illa I, Pradas J, V\u00e1zquez J, Codina M<\/div><div class=\"cnt_rev\">Med Clin (Barc)<\/div><\/div><\/div><\/div><\/div>\n<div id=\"gtx-trans\" style=\"position: absolute; left: 69px; top: 39.9688px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":312,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-336","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Miast\u00e8nia Gravis - Neuromuscular BCN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Miast\u00e8nia Gravis - Neuromuscular BCN\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/\" \/>\n<meta property=\"og:site_name\" content=\"Neuromuscular BCN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-29T08:55:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@NMDSantPau\" \/>\n<meta name=\"twitter:label1\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/\",\"url\":\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/\",\"name\":\"Miast\u00e8nia Gravis - Neuromuscular BCN\",\"isPartOf\":{\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg\",\"datePublished\":\"2025-03-27T05:17:00+00:00\",\"dateModified\":\"2025-04-29T08:55:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#primaryimage\",\"url\":\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg\",\"contentUrl\":\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/www.neuromuscularbcn.org\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Miast\u00e8nia Gravis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/#website\",\"url\":\"https:\/\/www.neuromuscularbcn.org\/ca\/\",\"name\":\"Neuromuscular BCN\",\"description\":\"Neuromuscular BCN - Unidad Neuromuscular del hospital de Sant Pau\",\"publisher\":{\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/#organization\"},\"alternateName\":\"Neuromuscular BCN - Unidad Neuromuscular del hospital de Sant Pau\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.neuromuscularbcn.org\/ca\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/#organization\",\"name\":\"Neuromuscular BCN - Sant Pau\",\"url\":\"https:\/\/www.neuromuscularbcn.org\/ca\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/06\/cropped-favicon_logotip.png\",\"contentUrl\":\"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/06\/cropped-favicon_logotip.png\",\"width\":512,\"height\":512,\"caption\":\"Neuromuscular BCN - Sant Pau\"},\"image\":{\"@id\":\"https:\/\/www.neuromuscularbcn.org\/ca\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/NMDSantPau\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Miast\u00e8nia Gravis - Neuromuscular BCN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/","og_locale":"ca_ES","og_type":"article","og_title":"Miast\u00e8nia Gravis - Neuromuscular BCN","og_url":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/","og_site_name":"Neuromuscular BCN","article_modified_time":"2025-04-29T08:55:28+00:00","og_image":[{"url":"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@NMDSantPau","twitter_misc":{"Temps estimat de lectura":"11 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/","url":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/","name":"Miast\u00e8nia Gravis - Neuromuscular BCN","isPartOf":{"@id":"https:\/\/www.neuromuscularbcn.org\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#primaryimage"},"image":{"@id":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#primaryimage"},"thumbnailUrl":"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg","datePublished":"2025-03-27T05:17:00+00:00","dateModified":"2025-04-29T08:55:28+00:00","breadcrumb":{"@id":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#primaryimage","url":"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg","contentUrl":"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/04\/slider2-1024x210-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.neuromuscularbcn.org\/ca\/recerca\/mal-neuromusculars-autoimmunes\/miastenia-gravis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.neuromuscularbcn.org\/ca\/"},{"@type":"ListItem","position":2,"name":"Miast\u00e8nia Gravis"}]},{"@type":"WebSite","@id":"https:\/\/www.neuromuscularbcn.org\/ca\/#website","url":"https:\/\/www.neuromuscularbcn.org\/ca\/","name":"Neuromuscular BCN","description":"Neuromuscular BCN - Unidad Neuromuscular del hospital de Sant Pau","publisher":{"@id":"https:\/\/www.neuromuscularbcn.org\/ca\/#organization"},"alternateName":"Neuromuscular BCN - Unidad Neuromuscular del hospital de Sant Pau","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.neuromuscularbcn.org\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.neuromuscularbcn.org\/ca\/#organization","name":"Neuromuscular BCN - Sant Pau","url":"https:\/\/www.neuromuscularbcn.org\/ca\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.neuromuscularbcn.org\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/06\/cropped-favicon_logotip.png","contentUrl":"https:\/\/www.neuromuscularbcn.org\/wp-content\/uploads\/2025\/06\/cropped-favicon_logotip.png","width":512,"height":512,"caption":"Neuromuscular BCN - Sant Pau"},"image":{"@id":"https:\/\/www.neuromuscularbcn.org\/ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NMDSantPau"]}]}},"_links":{"self":[{"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/pages\/336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/comments?post=336"}],"version-history":[{"count":4,"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/pages\/336\/revisions"}],"predecessor-version":[{"id":3078,"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/pages\/336\/revisions\/3078"}],"up":[{"embeddable":true,"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/pages\/312"}],"wp:attachment":[{"href":"https:\/\/www.neuromuscularbcn.org\/ca\/wp-json\/wp\/v2\/media?parent=336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}